

BEST AVAILABLE COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David R. Lindsay
Appl. No. : 09/943,072
Filed : August 30, 2001
Title : Method and Composition for Reducing the Danger and Preventing
the Abuse of Controlled Release Pharmaceutical Formulations

Gr./A.U. : 1639
Examiner : M. Baker

Docket No. : LIDR5001JL

I hereby certify that this paper is being
facsimile transmitted to the U. S. Patent and
Trademark Office (Fax No. 703/308-4315) on
February 21, 2003.

Heidi V. Sullivan

Date: February 21, 2003

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO OFFICE ACTION AND
REQUIREMENT FOR RESTRICTION

Sir:

In response to Applicant's interpretation of the Election/Restriction Action of January 22, 2003, Applicant, while reserving the right to continue to pursue all claims pending, hereby elects one species of each of the following for purposes of search:

Species 1: The pharmaceutical formulation referred to in claims 1 and 11, in which the active ingredient of the pharmaceutical composition referred to in these claims is Morphine Sulfate.

Species 2: The pharmaceutical formulation referred to in claims 1 and 11, in which the antagonist referred to in these claims is Naltrexone.

Species 3: The pharmaceutical formulation referred to in claims 1 and 11, in which the dosage form of the pharmaceutical composition referred to in these claims is Controlled Release Capsule, Pills, and the dosage form of the elected antagonist referred to above and in these claims is Plastic.

09/943,072

BEST AVAILABLE COPY Attorney Locket No. LIDR5001JL

In view of the complexity of both the subject matter and procedure, the Examiner is requested to contact the undersigned if Applicant appears to have misinterpreted the Election/Restriction action. In such event, more specific guidance is also requested as to what the Examiner is seeking. Applicant will respond promptly.

Respectfully submitted,



Joshua L. Price
Registration No. 50,766
Attorney for Applicant

Customer No. 029889
919/683-5514
Dated: February 21, 2003